JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Springer, K. L.
Right arrow Articles by Weinberg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Springer, K. L.
Right arrow Articles by Weinberg, A.
Journal of Clinical Microbiology, January 2005, p. 208-213, Vol. 43, No. 1
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.1.208-213.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients

Kathryn L. Springer,1 Sunwen Chou,2 Shaobing Li,1 Roger H. Giller,3 Ralph Quinones,3 James E. Shira,3 and Adriana Weinberg1,4*

Division of Infectious Diseases,1 Pediatric Infectious Diseases, University of Colorado Health Sciences Center,4 The Children's Hospital, Denver, Colorado,3 VA Medical Center and Oregon Health Sciences University, Portland, Oregon2

Received 9 June 2004/ Returned for modification 27 August 2004/ Accepted 10 September 2004

Infection with cytomegalovirus (CMV) remains a significant cause of morbidity and mortality among hematopoietic cell transplant (HCT) recipients. We describe two pediatric HCT recipients who developed persistent and severe drug-resistant CMV infections. CMV resistance to foscarnet and ganciclovir was detected after only 6 and 11 weeks of therapy, respectively. Viral pol mutations associated with drug resistance in these patients included T838A (a novel mutation) and D588N, which were shown by marker transfer to confer foscarnet and multidrug resistance, respectively. Each of these mutations significantly reduced in vitro replication of CMV, suggesting that they may decrease viral fitness. This finding was further supported by the disappearance of mutations upon withdrawal of antiviral pressure in one patient. Novel antivirals or combination therapy may be required for the treatment of drug-resistant CMV in HCT recipients and perhaps in other severely immunocompromised patients.


* Corresponding author. Mailing address: University of Colorado Health Sciences Center, 4200 E. 9th Ave., C-227, Denver, CO 80220. Phone: (303) 315-4624. Fax: (303) 315-1787. E-mail: adriana.weinberg{at}uchsc.edu.


Journal of Clinical Microbiology, January 2005, p. 208-213, Vol. 43, No. 1
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.1.208-213.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.